Fascin-1 and its role as a serological marker in prostate cancer: a prospective case-control study

Octavian Sabin Tătaru, Orsolya Martha, Felice Crocetto, Biagio Barone, Septimiu Voidazan, Angela Borda, Anca Sin, Adina Hutanu, Andrada Loghin, Ileana Sin, Daniel Porav-Hodade, Calin Bogdan Chibelean, Liliana Vartolomei, Giuseppe Lucarelli, Matteo Ferro, Virgil Gheorghe Osan, Carlo Buonerba, Mihai Dorin Vartolomei

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: This study aims to investigate any modification of serological FSCN1 in prostate cancer patients compared with patients without neoplasia.

Material & methods: Clinical data and blood specimens from patients with and without prostate cancer were obtained. A quantitative sandwich ELISA method was used to determine serological values of FSCN1.

Results: Although serum values of FSCN1 were dissimilar in the two cohorts of patients (6.90 vs 7.33 ng/ml), the difference was not statistically significant (p = 0.20). Serum values of FSCN1 stratified for Gleason score groups were not significantly distinguishable (p = 0.65). A negative correlation (rho = -0.331; p = 0.009) was reported between FSCN1 and age.

Conclusion: Further studies are required to evaluate a possible diagnostic role of FSCN1 in prostate cancer.

Original languageEnglish
Pages (from-to)FSO745
JournalFuture Science OA
Volume7
Issue number9
DOIs
Publication statusPublished - Oct 2021

Fingerprint

Dive into the research topics of 'Fascin-1 and its role as a serological marker in prostate cancer: a prospective case-control study'. Together they form a unique fingerprint.

Cite this